MedTrace Logo

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

NCT05918133 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-03-11

No results posted yet for this study

Summary

Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.

Conditions

Interventions

DRUG

PM8002

IV infusion

DRUG

nab-paclitaxel

IV infusion

Sponsors & Collaborators

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Wu Jiong · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918133 on ClinicalTrials.gov